Ignite Creation Date:
2024-05-06 @ 4:08 PM
Last Modification Date:
2024-10-26 @ 2:04 PM
Study NCT ID:
NCT04881916
Status:
RECRUITING
Last Update Posted:
2024-03-18
First Post:
2021-05-06
Brief Title:
Immune and Genomic Markers in ALK NSCLC
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Study Overview
Official Title:
Elucidating Novel Immune and Genomic Markers for ALK ENIGMA
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to obtain and study clinical history and tissue and saliva specimens if available from participants with Anaplastic Lymphoma Kinase-ALK Non-Small Lung CancerNSCLC
Detailed Description:
The purpose of this study is to establish a registry of clinical data and tumor specimens of patients with advanced ALK non-small lung cancer NSCLC defined as NSCLC harboring an ALK gene rearrangement This will allow in-depth comprehensive genomic and immunophenotypic analyses of ALK tumors Together with the clinical data these biologic specimens will enable the conduct of basic and translational research to identify genomic and immunologic markers associated with clinical outcomes for ALK patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None